IRLA IRulya Therapeutics Inc.

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

IRLA — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.4B
Employees
38
List Date
2019-05-09
CIK
0001662774
Next Earnings
2026-11-11
EPS Forecast
($1.39)
Headquarters
South San Francisco, CA
Homepage
https://www.quincetx.com

IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SA…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
Insufficient price history — listed 2743 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Loading technical indicators...
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All IRLA news →

IRLA Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Insufficient price history — listed 2743 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

IRLA Institutional Ownership (13F)

Filings for 2026-06-30 · 6 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

27 filers339,783 shares$17.61M value
# Filer Shares Value % of Total % of Float Period
1 Balyasny Asset Management L.P. 69,967 $12.56M 71.34% — 2026-06-30
2 Ikarian Capital, LLC 72,251 $1.31M 7.46% — 2026-06-30
3 Millennium Management LLC Custodian 70,779 $1.29M 7.31% — 2026-06-30
4 Squadron Capital Management LLC 40,375 $734.42K 4.17% — 2026-06-30
5 Shay Capital LLC 17,468 $329.27K 1.87% — 2026-06-30
6 Geode Capital Management, LLC Custodian 9,741 $302.12K 1.72% — 2026-09-30
7 BOOTHBAY FUND MANAGEMENT, LLC 13,911 $253.04K 1.44% — 2026-06-30
8 Jane Street Group, LLC Custodian 12,642 $229.96K 1.31% — 2026-06-30
9 Vanguard Capital Management LLC 12,044 $219.08K 1.24% — 2026-06-30
10 Cormorant Asset Management, LP 5,498 $100.01K 0.57% — 2026-06-30
11 UBS Group AG Custodian 4,730 $86.04K 0.49% — 2026-06-30
12 Morgan Stanley Custodian 4,084 $74.29K 0.42% — 2026-06-30
13 Vanguard Fiduciary Trust Co 3,614 $65.74K 0.37% — 2026-06-30
14 BlackRock, Inc. Custodian 1,702 $30.96K 0.18% — 2026-06-30
15 Tower Research Capital LLC (TRC) Custodian 567 $10.31K 0.06% — 2026-06-30
16 Gen-Wealth Partners Inc 166 $5.15K 0.03% — 2026-09-30
17 Operose Advisors LLC 159 $2.89K 0.02% — 2026-06-30
18 Fortitude Family Office, LLC 41 $1.27K <0.01% — 2026-09-30
19 BFC Planning, Inc. 14 $255 <0.01% — 2026-06-30
20 Parallel Advisors, LLC 6 $186 <0.01% — 2026-09-30
21 Wells Fargo & Company Custodian 10 $182 <0.01% — 2026-06-30
22 Allworth Financial LP Custodian 8 $146 <0.01% — 2026-09-30
23 Westside Investment Management, Inc. 1 $31 <0.01% — 2026-09-30
24 Steward Partners Investment Advisory, LLC 1 $18 <0.01% — 2026-06-30
25 JDM Financial Group LLC 1 $18 <0.01% — 2026-06-30
2 filers$3.11M notional
# Filer Notional Value % of Total Period
1 TUDOR INVESTMENT CORP ET AL $2.11M 67.80% 2026-06-30
2 Susquehanna International Group, LLP Custodian $1.00M 32.20% 2026-06-30
1 filers$2.14M notional
# Filer Notional Value % of Total Period
1 TUDOR INVESTMENT CORP ET AL $2.14M 100.00% 2026-06-30

IRLA Board & Officers

As of SEC filings through Oct 19, 2026

Directors 12

Officers 5

  • Dirk Thye · CEO and CMO · listed since Jun 2025
  • Charles S. Ryan · President · since Sep 1, 2023
  • John Militello · Chief Financial Officer · since Oct 8, 2026
  • Keith R. Fandrick · Chief Operating Officer · since Oct 8, 2026
  • Brigette Roberts · Chief Corp. Affairs Officer · since May 18, 2026
Changes in the last 10 years (69)
Oct 8, 2026Leone D Patterson became a director
Oct 8, 2026Keith R. Fandrick became Chief Operating Officer
Oct 8, 2026John Militello became Chief Financial Officer
Oct 8, 2026John Drayton Wise became a director
Oct 8, 2026James Elwood Valentine became a director
Oct 8, 2026Catherine M. Bonuccelli became a director
Oct 7, 2026The company announced the departure of Brendan Hannah as Cbo, COO & Cco in an SEC filing
May 18, 2026Brigette Roberts became a director
May 18, 2026Brigette Roberts became Chief Corp. Affairs Officer
Jan 30, 2026The company announced the departure of June Bray from the board in an SEC filing
Jun 23, 2025Dirk Thye listed as CEO and CMO (previously CEO and Chief Medical Officer) in SEC filings
Feb 11, 2025Brendan Hannah listed as Cbo, COO & Cco (previously Chief Business Officer and COO) in SEC filings
Feb 15, 2024Rajiv Patni became a director
Feb 2, 2024Dirk Thye listed as CEO and Chief Medical Officer (previously Chief Executive Officer) in SEC filings
Oct 26, 2023Brendan Hannah listed as Chief Business Officer and COO (previously Chief Business Officer) in SEC filings
Oct 23, 2023Luca Benatti became a director
Oct 23, 2023Guenter Janhofer became Chief Scientific Officer
Sep 1, 2023Charles S. Ryan became President
Jul 24, 2023The company announced the departure of Karen L. Smith as Chief Medical Officer in an SEC filing
Mar 27, 2023The company announced the departure of Philip S Low from the board in an SEC filing
Not reported recently (10)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

IRLA Proposed Insider Sales (Form 144)

Latest: 2026-11-05
Last 30d: 2 filings · $237K notice value  ·  Last 90d: 2 filings · $237K notice value · 2 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Dirk Thye (1, $133K) · Blue Devil Trust (1, $104K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-05 Blue Devil Trust Former Board Member 3,471 $103.5K 2026-10-09 Merrill Lynch — EDGAR
2026-10-21 Dirk Thye Officer 3,700 $133.3K 2026-10-21 MERRILL — EDGAR
2025-12-29 LUCA BENATTI OFFICER 50,000 $173.2K 2025-12-26 MERRILL — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-19
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-10-19 Regulation FD disclosure EDGAR
2026-10-09 Director or officer change · Bylaws or fiscal year change · Regulation FD disclosure · Other events EDGAR
2026-10-06 Director or officer change · Bylaws or fiscal year change · Shareholder vote results EDGAR
2026-10-02 Director or officer change EDGAR
2026-09-14 Acquisition or sale completed · Director or officer change EDGAR
2026-09-04 Listing standards notice EDGAR
2026-08-27 Director or officer change EDGAR
2026-08-17 Other events EDGAR
2026-08-14 Earnings results EDGAR
2026-07-31 Director or officer change EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-08-14 0001193125-26-352201 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

IRLA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
AMGN Amgen Inc $251.6B 26.9 +8.2% +41.3% 35
GILD Gilead Sciences Inc $210.0B — +6.5% +39.7% 45
MRNA Moderna, Inc. Common Stock $108.8B — −27.6% +711.0% 46
ARGX argenx SE American Depositary Shares $60.5B — — +15.1% 57
RVMD Revolution Medicines, Inc. Common Stock $43.3B — — +143.2% 59
BIIB Biogen Inc. Common Stock $37.7B 107.6 +2.3% +41.6% 100
BNTX BioNTech SE American Depositary Share $21.7B — — −10.0% 42
EXEL Exelixis Inc $17.5B 21.0 +9.1% +61.3% 23
IRLA IRulya Therapeutics Inc. Common Stock $366M — — — —
Peer median $51.9B 26.9 +6.5% +41.5% 46

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.